AU2021343475A1 - Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) - Google Patents
Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) Download PDFInfo
- Publication number
- AU2021343475A1 AU2021343475A1 AU2021343475A AU2021343475A AU2021343475A1 AU 2021343475 A1 AU2021343475 A1 AU 2021343475A1 AU 2021343475 A AU2021343475 A AU 2021343475A AU 2021343475 A AU2021343475 A AU 2021343475A AU 2021343475 A1 AU2021343475 A1 AU 2021343475A1
- Authority
- AU
- Australia
- Prior art keywords
- cltx
- cca
- blood
- dosing regimen
- period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063080165P | 2020-09-18 | 2020-09-18 | |
| US63/080,165 | 2020-09-18 | ||
| US202163159397P | 2021-03-10 | 2021-03-10 | |
| US63/159,397 | 2021-03-10 | ||
| PCT/US2021/050677 WO2022060987A1 (en) | 2020-09-18 | 2021-09-16 | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021343475A1 true AU2021343475A1 (en) | 2023-06-01 |
| AU2021343475A9 AU2021343475A9 (en) | 2024-05-02 |
Family
ID=78087574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021343475A Pending AU2021343475A1 (en) | 2020-09-18 | 2021-09-16 | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220087961A1 (https=) |
| EP (1) | EP4213829A1 (https=) |
| JP (1) | JP2023542932A (https=) |
| KR (1) | KR20230112609A (https=) |
| AU (1) | AU2021343475A1 (https=) |
| CA (1) | CA3192684A1 (https=) |
| IL (1) | IL301409A (https=) |
| MX (1) | MX2023003129A (https=) |
| TW (1) | TW202227046A (https=) |
| WO (1) | WO2022060987A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230106582A (ko) | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
| EP4698162A1 (en) * | 2023-04-21 | 2026-02-25 | Calcilytix Therapeutics, Inc. | Treatment of hypoparathyroidism using triphenyl calcilytic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407097A (pt) * | 2003-04-23 | 2006-01-24 | Japan Tobacco Inc | Antagonista do casr |
| KR20230106582A (ko) * | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
-
2021
- 2021-09-16 AU AU2021343475A patent/AU2021343475A1/en active Pending
- 2021-09-16 JP JP2023518198A patent/JP2023542932A/ja active Pending
- 2021-09-16 CA CA3192684A patent/CA3192684A1/en active Pending
- 2021-09-16 WO PCT/US2021/050677 patent/WO2022060987A1/en not_active Ceased
- 2021-09-16 US US17/477,198 patent/US20220087961A1/en active Pending
- 2021-09-16 MX MX2023003129A patent/MX2023003129A/es unknown
- 2021-09-16 EP EP21790717.9A patent/EP4213829A1/en active Pending
- 2021-09-16 IL IL301409A patent/IL301409A/en unknown
- 2021-09-16 KR KR1020237012476A patent/KR20230112609A/ko active Pending
- 2021-09-17 TW TW110134985A patent/TW202227046A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023542932A (ja) | 2023-10-12 |
| KR20230112609A (ko) | 2023-07-27 |
| TW202227046A (zh) | 2022-07-16 |
| WO2022060987A1 (en) | 2022-03-24 |
| IL301409A (en) | 2023-05-01 |
| EP4213829A1 (en) | 2023-07-26 |
| AU2021343475A9 (en) | 2024-05-02 |
| US20220087961A1 (en) | 2022-03-24 |
| CA3192684A1 (en) | 2022-03-24 |
| MX2023003129A (es) | 2023-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Christensson et al. | Hypercalcemia and primary hyperparathyroidism: prevalence in patients receiving thiazides as detected in a health screen | |
| US20220323445A1 (en) | Reducing immunogenicity to pegloticase | |
| KR100445946B1 (ko) | 폐고혈압 치료법 | |
| Palmer | A physiologic-based approach to the evaluation of a patient with hyperkalemia | |
| US20230173035A1 (en) | Reducing immunogenicity to pegloticase | |
| US6645959B1 (en) | Method for treating postoperative ileus | |
| US20220087961A1 (en) | Treatment methods of triphenyl calcilytic compounds | |
| US20220409620A1 (en) | Reducing immunogenicity to pegloticase | |
| US20090239844A1 (en) | Ace inhibitor-vasopressin antagonist combinations | |
| Pandey et al. | Use of 2MD, a novel oral calcitriol analog, in hemodialysis patients with secondary hyperparathyroidism | |
| CN116916907A (zh) | 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物 | |
| EP1253945B1 (en) | Ace inhibitor-vasopressin antagonist combinations | |
| EP1280555B1 (en) | Pharmaceutical composition comprising furosemide and conivaptan for the treatment of congestive heart failure | |
| TW202506101A (zh) | 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療 | |
| US20240423961A1 (en) | 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones | |
| US20250222003A1 (en) | Pharmaceutical composition for treating solid tumors | |
| WO2026032924A1 (en) | Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough | |
| US20210085711A1 (en) | Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease | |
| Sato et al. | Hypomagnesemia Causing Convulsions in a Patient Taking a Proton Pump Inhibitor: A Case Report | |
| WO2026078027A1 (en) | Dosage regimens for camlipixant in treating chronic cough | |
| Moretz | Drug Class Literature Scan: Iron Replacement, Oral | |
| Matsumoto et al. | Hypercalcemia with the Oral Administration of Active Vitamin D3 and Chinese Herbal Medicine | |
| WO2025235883A1 (en) | Acoramidis for use in the treatment of renal dysfunction | |
| CN120981229A (zh) | 用于治疗先天性肾上腺皮质增生症的组合物和方法 | |
| CN118829427A (zh) | 治疗腹型肥胖、高甘油三酯血症和/或血糖受损受试者的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |